Prourocare Medical (OTCMKTS:PUMD) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk & Volatility

Prourocare Medical has a beta of 8.37, meaning that its share price is 737% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Prourocare Medical and Sensus Healthcare, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prourocare Medical 0 0 0 0 N/A
Sensus Healthcare 0 1 4 0 2.80

Sensus Healthcare has a consensus target price of $12.25, indicating a potential upside of 109.40%. Given Sensus Healthcare’s higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Prourocare Medical.


This table compares Prourocare Medical and Sensus Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prourocare Medical N/A N/A N/A
Sensus Healthcare -10.21% -16.98% -11.03%

Institutional & Insider Ownership

8.2% of Sensus Healthcare shares are owned by institutional investors. 29.3% of Prourocare Medical shares are owned by company insiders. Comparatively, 41.1% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Prourocare Medical and Sensus Healthcare’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prourocare Medical N/A N/A N/A N/A N/A
Sensus Healthcare $20.59 million 4.57 -$3.71 million ($0.28) -20.89

Prourocare Medical has higher earnings, but lower revenue than Sensus Healthcare.


Sensus Healthcare beats Prourocare Medical on 5 of the 9 factors compared between the two stocks.

Prourocare Medical Company Profile

ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.

Receive News & Ratings for Prourocare Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prourocare Medical and related companies with's FREE daily email newsletter.